Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis.
Atherosclerosis
Cyclophosphamide
Immune system
Inflammation
Journal
International journal of cardiology. Heart & vasculature
ISSN: 2352-9067
Titre abrégé: Int J Cardiol Heart Vasc
Pays: Ireland
ID NLM: 101649525
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
received:
05
12
2019
revised:
28
04
2020
accepted:
30
04
2020
entrez:
25
6
2020
pubmed:
25
6
2020
medline:
25
6
2020
Statut:
epublish
Résumé
Atherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of survival of patients with severe atherosclerosis has been reported after CPA treatment, but the underlying mechanism is still poorly understood. We have investigated the effects of CPA in a murine model of atherosclerosis. Continuous oral administration of low-dose CPA (20 mg/kg/day) prevented atherosclerosis in apolipoprotein E-deficient (apoE The results demonstrate that oral treatment with CPA inhibits initiation and progression of atherosclerosis in the apoE
Sections du résumé
BACKGROUND
BACKGROUND
Atherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of survival of patients with severe atherosclerosis has been reported after CPA treatment, but the underlying mechanism is still poorly understood.
METHODS AND RESULTS
RESULTS
We have investigated the effects of CPA in a murine model of atherosclerosis. Continuous oral administration of low-dose CPA (20 mg/kg/day) prevented atherosclerosis in apolipoprotein E-deficient (apoE
CONCLUSIONS
CONCLUSIONS
The results demonstrate that oral treatment with CPA inhibits initiation and progression of atherosclerosis in the apoE
Identifiants
pubmed: 32577494
doi: 10.1016/j.ijcha.2020.100529
pii: S2352-9067(19)30289-1
pii: 100529
pmc: PMC7300380
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100529Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
None declared.
Références
Isr Med Assoc J. 2005 Apr;7(4):266-7
pubmed: 15847211
Circ Res. 2002 May 31;90(10):1039-40
pubmed: 12039791
Am J Pathol. 2003 Sep;163(3):1117-25
pubmed: 12937153
Circ J. 2009 Jun;73(6):994-1001
pubmed: 19430164
Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1596-601
pubmed: 15665085
Am J Pathol. 2008 Jun;172(6):1500-8
pubmed: 18467709
Int J Biol Macromol. 2018 Sep;116:8-15
pubmed: 29730008
Arch Toxicol. 2004 Jul;78(7):397-401
pubmed: 15014928
Arch Intern Med. 1981 May;141(6):758-63
pubmed: 7235784
J Clin Invest. 2011 May;121(5):2025-36
pubmed: 21505265
Circ J. 2010 Feb;74(2):213-20
pubmed: 20065609
Immunol Res. 2010 Jul;47(1-3):179-84
pubmed: 20087683
Cancer Res. 2002 May 15;62(10):2731-5
pubmed: 12019144
J Clin Invest. 1998 Aug 15;102(4):671-8
pubmed: 9710434
Circulation. 2008 Jun 24;117(25):3168-70
pubmed: 18574058
Atherosclerosis. 2007 Sep;194(1):125-33
pubmed: 17109863
Nat Rev Immunol. 2008 Oct;8(10):802-15
pubmed: 18825131
J Cardiol Cases. 2016 Mar 15;13(6):185-188
pubmed: 30546642
Blood. 1986 Nov;68(5):1114-8
pubmed: 3533179
Thromb Haemost. 2015 Oct;114(4):835-47
pubmed: 26063196
Cardiol Rev. 2014 May-Jun;22(3):147-51
pubmed: 24618929
Arterioscler Thromb Vasc Biol. 2002 Mar 1;22(3):456-61
pubmed: 11884290
Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):378-88
pubmed: 25524776
Vascul Pharmacol. 2005 Nov;43(5):357-63
pubmed: 16271517
Nat Rev Drug Discov. 2011 May;10(5):365-76
pubmed: 21532566
Nature. 2005 Apr 7;434(7034):782-6
pubmed: 15815632
Arterioscler Thromb Vasc Biol. 2002 Nov 1;22(11):1892-8
pubmed: 12426221
J Clin Invest. 2007 Jan;117(1):195-205
pubmed: 17200719
Front Immunol. 2014 Nov 12;5:579
pubmed: 25429291
Arterioscler Thromb Vasc Biol. 2015 Aug;35(8):1770-3
pubmed: 26088575
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
J Clin Invest. 2002 Mar;109(6):745-53
pubmed: 11901183
Endocr Metab Immune Disord Drug Targets. 2009 Sep;9(3):237-47
pubmed: 19594418
Trends Immunol. 2004 Dec;25(12):677-86
pubmed: 15530839
J Mol Cell Cardiol. 2008 Aug;45(2):168-75
pubmed: 18502445
Atherosclerosis. 2011 Mar;215(1):1-8
pubmed: 21130454
Int Immunopharmacol. 2001 Feb;1(2):307-19
pubmed: 11360931
Rheumatol Int. 2006 Mar;26(5):454-60
pubmed: 16025335
J Exp Med. 2010 Aug 2;207(8):1579-87
pubmed: 20603314
Circ Res. 2014 May 9;114(10):1640-60
pubmed: 24812352
Int Immunopharmacol. 2011 Sep;11(9):1293-7
pubmed: 21530682
Neurol Sci. 2008 Sep;29 Suppl 2:S233-4
pubmed: 18690502
Br J Radiol. 2000 Oct;73(874):1112-4
pubmed: 11271907
J Clin Invest. 2001 Jul;108(2):251-9
pubmed: 11457878
Nature. 2002 Dec 19-26;420(6917):868-74
pubmed: 12490960
J Immunol. 2010 Oct 1;185(7):4410-9
pubmed: 20817865
Pediatrics. 2000 Jun;105(6):E78
pubmed: 10835091
Curr Opin Rheumatol. 2015 Jan;27(1):63-70
pubmed: 25405822
J Immunol. 2005 Apr 1;174(7):4389-99
pubmed: 15778404
Life Sci. 2019 Feb 1;218:112-131
pubmed: 30552952
Intern Med. 2013;52(20):2311-5
pubmed: 24126391
Circulation. 2001 Jul 10;104(2):197-202
pubmed: 11447086
Circulation. 2000 Mar 28;101(12):1372-8
pubmed: 10736279
Joint Bone Spine. 2013 Jul;80(4):374-9
pubmed: 23237994
Cancer Treat Rev. 2016 Jan;42:3-9
pubmed: 26620820
Annu Rev Immunol. 2009;27:669-92
pubmed: 19132917
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748